Experimental Drug Slows Decline In Alzheimer’s Patients
Combined results from two studies show that Solanezumab, an Alzheimer’s drug being developed by Eli Lilly & Co., might slow mental decline, particularly in milder Alzheimer’s cases. The results were announced on Monday by researchers at a conference of the American Neurological Association in Boston. While the separate studies showed that the drug did not […]
min read